In TCGA cohort patients with oligoastrocytoma, astrocytoma, oligodendroglioma as well as IDH wild or mutation, showed significantly different outcomes between low‐risk and high‐risk groups (Figure 7A–E), while in CGGA cohort patients just with oligoastrocytoma, astrocytoma, and IDH mutation showed significantly different outcomes. This evidence concerns the gene IDH2 and astrocytoma (excluding glioblastoma).